Braveheart Bio, Inc. (NASDAQ:BRVE) Stock Has Consensus Target Price of $45.25

Key Points

• Analyst sentiment is moderately bullish: Five of six covering brokerages rate Braveheart Bio a buy, with an average 12-month price target of $45.25 versus the stock’s $19.21 opening price.
• Recent earnings fell well short of expectations: The company reported a quarterly loss of $2.51 per share, missing the consensus estimate of a $0.25 loss; analysts expect a full-year loss of $1.48 per share.
• Insiders have made significant purchases: Insiders bought 8.75 million shares worth approximately $157.5 million over the past 90 days, including a $19.8 million purchase by major shareholder Bio Fund IV.

Shares of Braveheart Bio, Inc. (NASDAQ:BRVE - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $45.25.

Several brokerages have commented on BRVE. Zacks Research raised Braveheart Bio to a "hold" rating in a report on Tuesday, September 1st. The Goldman Sachs Group assumed coverage on Braveheart Bio in a research note on Monday, August 31st. They set a "buy" rating and a $48.00 target price for the company. Cantor Fitzgerald assumed coverage on Braveheart Bio in a research report on Monday, August 31st. They set an "overweight" rating and a $40.00 target price on the stock. Jefferies Financial Group began coverage on shares of Braveheart Bio in a research note on Monday, August 31st. They issued a "buy" rating and a $48.00 price target on the stock. Finally, Wall Street Zen raised shares of Braveheart Bio to a "hold" rating in a report on Saturday, August 15th.

Braveheart Bio Price Performance

NASDAQ:BRVE opened at $19.21 on Tuesday. Braveheart Bio has a 52 week low of $17.86 and a 52 week high of $32.00. The firm has a market cap of $1.73 billion and a PE ratio of -7.65. The company's 50-day simple moving average is $24.50.

Braveheart Bio (NASDAQ:BRVE - Get Free Report) last released its quarterly earnings results on Tuesday, September 8th. The company reported ($2.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($2.26). As a group, equities research analysts expect that Braveheart Bio will post -1.48 earnings per share for the current year.

Insider Buying and Selling at Braveheart Bio

In related news, Director David Lubner purchased 55,555 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average cost of $18.00 per share, with a total value of $999,990.00. Following the purchase, the director owned 55,555 shares of the company's stock, valued at $999,990. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bio Fund Iv L.P. Ah purchased 1,100,000 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $19,800,000.00. Following the completion of the purchase, the insider directly owned 10,232,420 shares in the company, valued at $184,183,560. This represents a 12.05% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have bought 8,751,942 shares of company stock valued at $157,534,956.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.